Progenics Pharmaceuticals

302 articles with Progenics Pharmaceuticals

• Lantheus Holdings Announces Presentations Featuring its PSMA-Targeted Pipeline Product Candidates at the 2021 ASCO GU Annual Meeting

  2/4/2021

  Lantheus Holdings, Inc. (NASDAQ: LNTH) (the “Company”), the parent company of Lantheus Medical Imaging, Inc. and Progenics Pharmaceuticals, Inc., and a global leader in the development, manufacture and commercialization of innovative diagnostic and therapeutic agents and products, announced today three abstracts featuring its PSMA-targeted pipeline of product candidates have been selected for poster presentations at the upcoming 2021 American Society for Clinical Oncology Genitourinary

• Lantheus Holdings Announces Acceptance and Priority Review of New Drug Application for PyLTM (18F-DCFPyL), a PSMA-Targeted Prostate Cancer PET Imaging Agent

  12/9/2020

  Lantheus Holdings, Inc. and Progenics Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration has accepted the New Drug Application for PyLTM, a prostate specific membrane antigen -targeted positron emission tomography imaging agent for prostate cancer.

• Lantheus Holdings, Inc. Announces Agreement to Sell Its Puerto Rico Radiopharmacy and PET Manufacturing Facility and Enter into Long-Term Supply Agreement

  12/3/2020

  Lantheus Holdings, Inc. and Progenics Pharmaceuticals, Inc., and a global leader in the development, manufacture and commercialization of innovative diagnostic and therapeutic agents and products, announced its entry into a stock purchase agreement to sell its Puerto Rico radiopharmacy and positron emission tomography manufacturing facility to PharmaLogic Holdings Corp.

• CORRECTION: TIME CHANGE - Lantheus Holdings to Present at November 2020 Investor Conferences

  11/9/2020

  Lantheus Holdings, Inc., the parent company of Lantheus Medical Imaging, Inc., Progenics Pharmaceuticals, Inc. and EXINI Diagnostics AB, and a global leader in the development, manufacture and commercialization of innovative diagnostic and therapeutic agents and products, announced that management will present at two investor conferences in November.

• Lantheus Holdings to Showcase the Potential of PyL™ Imaging Agent at the Virtual Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2020 Annual Meeting

  7/1/2020

  Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH), the parent company of Lantheus Medical Imaging, Inc. and Progenics Pharmaceuticals, Inc., and a global leader in the development, manufacture and commercialization of innovative diagnostic and therapeutic agents and products, today announced that 17 abstracts highlighting PyL™ (18F-DCFPyL) have been selected for presentation at the virtual Society of Nuclear Medicine and Molecular Imaging

• Lantheus Completes Merger with Progenics

  6/22/2020

  Lantheus Holdings, Inc. announced that it has completed its previously announced merger with Progenics Pharmaceuticals, Inc., an oncology company developing innovative medicines and artificial intelligence to find, fight and follow cancer.

• Progenics Stockholders Approve Merger with Lantheus

  6/16/2020

  Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) (“Progenics”), an oncology company developing innovative medicines and artificial intelligence to find, fight and follow cancer, announced that at a special meeting of its stockholders held earlier today, Progenics’ stockholders voted to approve its proposed merger with Lantheus Holdings, Inc.

• Progenics to Present Results from the Phase 3 CONDOR Trial of PyL™ (18F-DCFPyL) in Prostate Cancer at the American Society of Clinical Oncology 2020 Virtual Scientific Program

  5/18/2020

  - Met Primary Endpoint with a Correct Localization Rate of 84.8–87.0% - - 63.9% Change in Disease Management Plan Based on PyL Imaging Results - - Planned NDA Submission On Track for Early Third Quarter 2020 - NEW YORK, May 18, 2020 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX), an oncology company developing innovative medicines and artificial intelligence to find, fight and follow cancer, today announced that the results from the Phase 3 CONDOR trial evaluating the

• Progenics Pharmaceuticals Announces First Quarter 2020 Financial Results and Business Update

  5/7/2020

  Pending Merger with Lantheus Holdings, Inc. for Combination of an Innovative Commercial Life Sciences Company with a Diversified Precision Diagnostics and Radiopharmaceutical Therapeutics Portfolio

• Progenics Pharmaceuticals Sets First Quarter 2020 Financial Results and Business Update Call for May 7

  4/23/2020

  Progenics Pharmaceuticals, Inc. (NASDAQ: PGNX), an oncology company developing innovative medicines and artificial intelligence to find, fight and follow cancer, today announced that it will host a conference call and webcast to review first quarter ended March 31, 2020 financial results on Thursday, May 7, 2020, at 8:30 a.m. ET. To participate, please dial (877) 250-8889 (domestic) or (720) 545-0001 (international) and reference conference ID 735

• Lantheus and Progenics Reschedule Their Respective Special Meetings of Stockholders for Proposed Merger

  4/2/2020

  Lantheus Holdings, Inc. and Progenics Pharmaceuticals, Inc. (NASDAQ: PGNX) (“Progenics”), an oncology company developing innovative medicines and artificial intelligence to find, fight and follow cancer, today ann

• PROGENICS PHARMACEUTICALS ANNOUNCES FOURTH QUARTER AND FULL-YEAR 2019 FINANCIAL RESULTS

  3/13/2020

  Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX) today announced financial results for the fourth quarter and full-year 2019.

• Progenics Pharmaceuticals Announces Presentations at the 2020 American Society of Clinical Oncology Genitourinary Cancers Symposium Annual Meeting (ASCO GU)

  2/6/2020

  Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX), an oncology company developing innovative targeted medicines and artificial intelligence to find, fight and follow cancer, today announced that three abstracts highlighting PyLTM (18F-DCFPyL), I-131 1095, and PSMA AI have been selected for oral and poster presentations at the upcoming American Society of Clinical Oncology Genitourinary Cancers Symposium Annual Meeting (ASCO GU)

• Progenics Pharmaceuticals Provides Update on Reconstituted Board’s Ongoing Strategic Review

  1/21/2020

  The Board of Directors of Progenics Pharmaceuticals, Inc., an oncology company developing innovative targeted medicines and artificial intelligence to find, fight and follow cancer, issued the following letter to shareholders

• Progenics Pharmaceuticals Announces Presentation at the 2020 SNMMI Mid-Winter Meeting

  1/16/2020

  Progenics is an oncology company focused on the development and commercialization of innovative targeted medicines and artificial intelligence to find, fight and follow cancer, including: therapeutic agents designed to treat cancer

• 

  Clinical Catch-Up: December 23-27

  12/30/2019

  With the holidays, it’s not surprising that it was a quiet week for clinical trial news. Nonetheless, some companies did have clinical trial stories to report. Here’s a look.
• 

  Progenics Plans to Seek Approval for Prostate Cancer Imaging Tool Following Phase III Results

  12/23/2019

  Shares of Progenics Pharmaceuticals are up more than 20% in premarket trading after the company announced positive top-line results from its Phase III prostate cancer imaging tool PyL.

• Progenics Pharmaceuticals Announces Phase 3 CONDOR Trial of PyL™ in Prostate Cancer Achieved Primary Endpoint

  12/23/2019

  Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX), an oncology company developing innovative targeted medicines and artificial intelligence to find, fight and follow cancer, today announced positive top line results from the Phase 3 CONDOR trial evaluating the diagnostic performance and clinical impact of PyL™ (18F-DCFPyL) in men with biochemical recurrence of prostate cancer.

• Progenics Pharmaceuticals to Announce and Host a Conference Call to Discuss Top Line Results from Phase 3 CONDOR Trial of PyL™ in Prostate Cancer on Monday, December 23rd

  12/22/2019

  Progenics Pharmaceuticals, Inc. announced that it will host a conference call to review the top line results from the Phase 3 CONDOR trial of PyL™ in men with biochemical recurrence of prostate cancer on Monday, December 23, 2019, at 8:00 a.m. ET.

• Progenics Pharmaceuticals Appoints David Mims as Interim Chief Executive Officer

  11/21/2019

  David W. Mims as interim Chief Executive Officer. Mr. Mims, a member of Progenics’ Board of Directors, will assume the leadership of the executive team while the Board of Directors conducts a search to identify a permanent Chief Executive Officer.